

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-260001	Application No. 09/821,719
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant John A. Lust, et al.	
		Filing Date March 29, 2001	Group Art Unit 1645

RECEIVED
SEP 10 2001
TECH CENTER 1600
2001

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
WY	AA	5,470,952	11/28/95	Stahl et al.			
	AB	5,844,099	12/01/98	Stahl et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	No
WY	AC							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
WY	AD	Alexanian and Dimopoulos, "The Treatment of Multiple Myeloma," <u>New Engl. J. Med.</u> , 1994, 330(7):484-489
	AE	Balkwill (ed.), <u>Cytokines – A Practical Approach</u> , 1991, IRL Press at Oxford University Press, Oxford, pp. 311-312
	AF	Bataille et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," <u>J. Clin. Invest.</u> , 1989, 84:2008-2011
	AG	Bataille et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," <u>Blood</u> , 1995, 86(2):685-691
	AH	Carter et al., "The role of interleukin-1 and tumour necrosis factor- α in human multiple myeloma," <u>Br. J. Haematol.</u> , 1990, 74:424-431
	AI	Carter et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," <u>Nature</u> , 1990, 344:633-638
	AJ	Costes et al., "Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production," <u>Br. J. Haematol.</u> , 1998, 103:1152-1160
	AK	Dinarello et al., "Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome," <u>JAMA</u> , 1993, 269(14):1829-1835
	AL	Dinarello, "Biologic Basis for Interleukin-1 in Disease," <u>Blood</u> , 1996, 87(6):2095-2147
	AM	Dinarello and Thompson, "Blocking IL-1: interleukin 1 receptor antagonist <i>in vivo</i> and <i>in vitro</i> ," <u>Immunol. Today</u> , 1991, 12(11):404-410
	AN	Donovan et al., "Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma," <u>Leukemia</u> , 1998, 12:593-600
	AO	Eisenberg et al., "Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist," <u>Nature</u> , 1990, 343:341-346
	AP	Greipp and Lust, "Pathogenetic Relation Between Monoclonal Gammopathies of Undetermined Significance and Multiple Myeloma," <u>Stem Cells</u> , 1995, 13(Suppl. 2):10-21
	AQ	Greipp and Witzig, "Biology and treatment of myeloma," <u>Curr. Opn. Oncol.</u> , 1996, 8:20-27
	AR	Grigorieva et al., "The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone," <u>Exp. Hematol.</u> , 1998, 26:597-603

Examiner Signature	Date Considered
	6/10/02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) O P E R A T I O N S Information Disclosure Statement SEP 07 2001 (use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-260001	Application No. 09/821,719
		Applicant John A. Lust, et al.	
		Filing Date March 29, 2001	Group Art Unit 1645


RECEIVED
TECH CENTER 1600
SEP 10 2001

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	AS ✓	Hannum et al., "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," <u>Nature</u> , 1990, 343:336-340	
	AT ✓	Hawley et al., "Expression of Retrovirally Transduced IL-1 α in IL-6-Dependent B Cells: A Murine Model of Aggressive Multiple Myeloma," <u>Growth Factors</u> , 1991, 5:327-338	
	AU ✓	Hilbert et al., "Interleukin 6 Is Essential for In Vivo Development of B Lineage Neoplasms," <u>J. Exp. Med.</u> , 1995, 182:243-248	
	AV ✓	Howard et al., "IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the IL-1 β Precursor at Two Distinct Sites and Does Not Cleave 31-kDa IL-1 α ," <u>J. Immunol.</u> , 1991, 147(9):2964-2969	
	AW ✓	Kawano et al., "Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas," <u>Nature</u> , 1988, 332:83-85	
	AX ✓	Kishimoto, "The Biology of Interleukin-6," <u>Blood</u> , 1989, 74:1-10	
	AY ✓	Klein et al., "Paracrine Rather Than Autocrine Regulation of Myeloma-Cell Growth and Differentiation by Interleukin-6," <u>Blood</u> , 1989, 73(2):517-526	
	AZ ✓	Klein et al., "Inhibiting IL-6 in Human Multiple Myeloma," <u>Curr. Topics Microbiol. Immunol.</u> , 1992, 182:237-244	
	AAA ✓	Kyle, "Newer Approaches to the Management of Multiple Myeloma," <u>Cancer</u> , 1993, 72(11):3489-3494	
	ABB ✓	Kyle, "'Benign' Monoclonal Gammopathy – After 20 to 35 Years of Follow-up," <u>Mayo Clin. Proc.</u> , 1993, 68:26-36	
	ACC ✓	Kyle and Greipp, "Smoldering Multiple Myeloma," <u>New Engl. J. Med.</u> , 1980, 302:1347-1349	
	ADD ✓	Kyle and Lust, "Monoclonal Gammopathies of Undetermined Significance," <u>Sem. Hematol.</u> , 1989, 26(3):176-200	
	AEE ✓	Lacy et al., "Comparison of Interleukin-1 β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma," <u>Blood</u> , 1999, 93:300-305	
	AFF ✓	Lust and Donovan, "The Role of Interleukin-1 β in the Pathogenesis of Multiple Myeloma," <u>Hematology/Oncology Clinics of North America</u> , 1999, 13(6):1117-1125	
	AGG ✓	March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," <u>Nature</u> , 1985, 315:641-647	
	AHH ✓	Nagata et al., "Interleukin 1 Autocrine Growth System in Human Multiple Myeloma," <u>Jpn. J. Clin. Oncol.</u> , 1991, 21:22-29	
	AII ✓	Oken et al., "Comparison of Melphalan and Prednisone with Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Multiple Myeloma," <u>Cancer</u> , 1997, 79:1561-1567	
	AJJ ✓	Parker et al., "Cancer Statistics, 1996," <u>CA – A Cancer Journal for Clinicians</u> , 1996, 46:5-27	
	AKK ✓	Portier et al., "In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma," <u>Eur. J. Immunol.</u> , 1991, 21:1759-1762	
	ALL ✓	Schwab et al., "Characterization of an Interleukin-6-Mediated Autocrine Growth Loop in the Human Multiple Myeloma Cell Line, U266," <u>Blood</u> , 1991, 77(3):587-593	
	AMM ✓	Sleath et al., "Substrate Specificity of the Protease That Processes Human Interleukin-1 β ," <u>J. Biol. Chem.</u> , 1990, 265(24):14526-14528	

Examiner Signature 	Date Considered 6/10/01
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-260001	Application No. 09/821,719
Information Disclosure Statement by Applicant SEP 07 2001 (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant John A. Lust, et al.	
		Filing Date March 29, 2001	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MK	ANN ✓	Tanihara et al., "A Synthetic Peptide Corresponding to 86-93 of the Human Type I IL-1 Receptor Binds Human Recombinant IL-1 (α and β) and Inhibits IL-1 Actions <i>in vitro</i> and <i>in vivo</i> ," <u>Biochem. Biophys. Res. Comm.</u> , 1992, 188(2):912-920
J	AOO	Torcia et al., "Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors," <u>Exp. Hematol.</u> , 1996, 24:868-874
J	APP ✓	Yamamoto et al., "Production of Interleukin 1 β , a Potent Bone Resorbing Cytokine, by Cultured Human Myeloma Cells," <u>Cancer Res.</u> , 1989, 49:4242-4246
	AQQ ✓	Zhang et al., "Interleukin-6 Is a Potent Myeloma-Cell Growth Factor in Patients With Aggressive Multiple Myeloma," <u>Blood</u> , 1989, 74:11-13

Examiner Signature 	Date Considered 6/11/01
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	